Category: Demonstrating
-
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
•
Investor EmpiresArticle Content Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved drug and 30 in development. Quantitative PSMA-PET imaging is required to determine patient eligibility for the first FDA-approved PSMA-targeted drug and is an inclusion criterion for ongoing trials. BOSTON, Sept. 15, 2024…
-
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
•
Investor EmpiresArticle Content Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved drug and 30 in development. Quantitative PSMA-PET imaging is required to determine patient eligibility for the first FDA-approved PSMA-targeted drug and is an inclusion criterion for ongoing trials. BOSTON, Sept. 15, 2024…